



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/CVMP/193333/2007
EMA/V/C/000059

Eurican Herpes 205 (*canine herpes virus (F205 strain) antigens*)

An overview of Eurican Herpes 205 and why it is authorised in the EU

What is Eurican Herpes 205 and what is it used for?

Eurican Herpes 205 is a veterinary vaccine used to immunise pregnant bitches to prevent mortality, clinical signs and lesions in puppies caused by canine herpes virus infections acquired in the first few days of life.

Eurican Herpes 205 contains the active substance canine herpes virus (F205 strain) antigens.

How is Eurican Herpes 205 used?

Eurican Herpes 205 is available as a powder and solvent that is made into an emulsion for injection under the skin. It can only be obtained with a prescription.

Eurican Herpes 205 is given as two 1-ml injections. The first injection is given either when the bitch is on heat or 7 – 10 days after the date of mating. The second injection is given 1 to 2 weeks before the expected date of whelping. The bitch should be revaccinated in the same way during each pregnancy.

For more information about using Eurican Herpes 205, see the package leaflet or contact your veterinarian or pharmacist.

How does Eurican Herpes 205 work?

Eurican Herpes 205 contains small amounts of canine herpes virus antigens. When injected, this small exposure helps the dog's immune system to produce antibodies against the canine herpes virus and to neutralize it. Once vaccinated, bitches will, through colostrum, give those antibodies to puppies. When exposed to canine herpes virus later in life, the puppies will either not become infected or have a much less serious infection. Eurican Herpes 205 is intended to protect the puppies from this infection during the first few days of life.



What benefits of Eurican Herpes 205 have been shown in studies?

Eurican Herpes 205 has been studied in three laboratory studies and two field trials. In one field trial the serological response (antibody production) was measured. In the other, a study was made of the effect of vaccination on the ability of bitches to breed in an infected kennel. The first laboratory study tested the dose needed to provide protection. The second study was carried out to show the protection of puppies from vaccinated bitches from canine herpes virus. Here Eurican Herpes 205 was compared with no vaccination (controls). The last one demonstrated that induction of antibodies is equivalent when bitches are vaccinated the day of heat or 7-10 days after mating.

Eurican Herpes 205 showed good protection from canine herpes virus. In the study to show the protection of puppies (from vaccinated bitches) from canine herpes virus, over 80% of the pups from the vaccinated bitches survived.

What are the risks associated with Eurican Herpes 205?

The injection of Eurican Herpes 205 may cause temporary oedema (fluid under the skin) at the injection site in up to 10% of animals. This side effect usually disappears within one week. Rarely, hypersensitivity (allergic) reactions may occur, which require treatment.

For the full list of side effects and restrictions of Eurican Herpes 205, see the package leaflet.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

Eurican Herpes 205 contains mineral oil. Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger. If someone is accidentally injected with this product, they must seek immediate medical advice even if only a very small amount is injected. The package leaflet should be taken to the doctor. If pain persists for more than 12 hours after medical examination, the doctor should be contacted again.

Why is Eurican Herpes 205 authorised in the EU?

The European Medicines Agency decided that Eurican Herpes 205's benefits are greater than its risks and it can be authorised for use in the EU.

Other information about Eurican Herpes 205

Eurican Herpes 205 received a marketing authorisation valid throughout the EU on 26 March 2001.

Further information on Eurican Herpes 205 can be found on the Agency's website:

ema.europa.eu/en/medicines/veterinary/EPAR/eurican-herpes-205

This overview was last updated in 03-2020.